Zhuochuming®-3T&E-DME Study (Treatment-naïve Patients)
A Prospective, Randomized Controlled, Open-label, Multicenter Clinical Trial of the Efficacy and Safety of Aflibercept Intravitreal Injection (Zhuochuming®) With a 3-month Loading Phase Followed by Treat-and-extend Regimen in Treatment-naïve Patients With Diabetic Macular Edema
The goal of this clinical trial is to understand whether Zhuochuming® (Aflibercept Intravitreal Injection) using a 3 loading doses followed by a treat-and-extend regimen (3+T&E) can treat patients with diabetic macular edema (DME) who have not received prior treatment. It will also evaluate the safety of Zhuochuming®.
The main questions it aims to answer are:
Can Zhuochuming® using the 3+T&E regimen improve patients' vision better than the traditional pro re nata (3+PRN) regimen?
How much can the macular edema (central retinal thickness) be reduced?
What medical problems (ocular or systemic) will participants experience while taking Zhuochuming®?
What is the difference in the number of injections needed over one year between the two regimens?
Researchers will directly compare Zhuochuming® (3+T&E regimen) with Zhuochuming® (3+PRN regimen) to see which regimen is more effective and convenient for treating DME.
Participants will:
Receive treatment and be followed for 52 weeks (about 1 year)
First receive 3 injections (one every 4 weeks), and then continue according to their assigned group:
T&E group: Injection intervals are gradually extended (up to 16 weeks) based on disease stability
PRN group: Follow-up visits every 4 weeks, with injections given only when needed
Visit the clinic at scheduled times (e.g., before each injection or every 4 weeks) for eye examinations (visual acuity, intraocular pressure, OCT, etc.)
Undergo regular blood tests (complete blood count, liver function, coagulation function, HbA1c, etc.)
Record any discomfort or side effects and report them to the doctor
Study population:
Patients with diabetic macular edema (DME) who have not received prior treatment, aged ≥18 years, and diagnosed with type 1 or type 2 diabetes.
Primary study endpoint:
Change in best-corrected visual acuity (BCVA) from baseline at week 52.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 4
Contactos e Locais
Locais de estudo
-
-
Liaoning
-
Dalian, Liaoning, China, 1160033
- The Third Peoples Hospital of Dalian
-
Contato:
- SHENG LI
- Número de telefone: +8618141159143
- E-mail: leoonnet@163.com
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Subject voluntarily participates in the study and signs the informed consent form.
- Subject is aged ≥18 years and has a diagnosis of type 1 or type 2 diabetes mellitus.
- Refractive status and axial length of the study eye: -6.00D < spherical equivalent < +6.00D, or 21 mm < axial length < 26 mm.
- Best-corrected visual acuity (BCVA) of the study eye at screening and baseline is between 78 and 24 ETDRS letters (approximately equivalent to Snellen 20/32 to 20/320).
- Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 3 days before the first dose and must use an acceptable method of contraception.
- Subject is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study requirements.
- The study eye has center-involving diabetic macular edema (DME), defined as central retinal thickness (CRT) ≥300 μm (or ≥320 μm assessed by Heidelberg Spectralis) confirmed by the reading center of the Third People's Hospital of Dalian (primary center) at baseline visit. The reading center is composed of three senior vitreoretinal specialists and experts from the functional examination department of the Third People's Hospital of Dalian.
- Visual impairment is primarily caused by DME.
Exclusion Criteria:
- Known hypersensitivity to any component of the study drug.
- Prior intraocular surgery in the study eye, including macular laser photocoagulation, panretinal photocoagulation, etc.
- Prior intraocular or periocular steroid treatment in the study eye.
- Prior intravitreal anti-VEGF therapy (e.g., ranibizumab, conbercept, bevacizumab) in the study eye.
- Prior photodynamic therapy in the study eye.
- Active ocular inflammation (including trace or more) in either eye.
- Aphakia or absence of the posterior capsule in the study eye (excluding pseudophakic eyes).
- History of corneal transplantation in the study eye.
- History of idiopathic or autoimmune uveitis in either eye.
- Uncontrolled glaucoma in the study eye (defined as intraocular pressure >25 mmHg despite anti-glaucoma medication) or history of glaucoma filtering surgery.
- Any history of vitreous hemorrhage in the study eye within 4 weeks prior to screening.
- Presence of other retinal diseases in the study eye, such as retinal detachment, retinal vein occlusion, etc.
- Inadequately controlled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥95 mmHg based on average of ≥2 measurements), allowing improvement with antihypertensive treatment; or history of hypertensive crisis or hypertensive encephalopathy.
- Severe cardiovascular disease (myocardial infarction or cerebrovascular accident), unstable arrhythmia, or unstable angina within 3 months prior to the first dose.
- Renal failure requiring dialysis or kidney transplantation.
- Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period.
- History of schizophrenia or substance abuse (psychoactive drugs).
- Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) study or the follow-up phase of an interventional study.
- Glycated hemoglobin (HbA1c) level ≥10%, and/or recent signs of uncontrolled diabetes (≥3 episodes of severe hypoglycemia within 3 months before baseline, or hospitalization due to acute hyperglycemia-related complications such as diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS), or other emergencies caused by severe hyperglycemia (e.g., dehydration, electrolyte disturbance, altered consciousness); or ≥2 episodes of DKA within 1 year before baseline, or ≥1 episode of DKA within 3 months before baseline).
- Presence of proliferative diabetic retinopathy (PDR) in the study eye.
- Ocular disease in the study eye that may confound interpretation of study results, including choroidal neovascularization (CNV) of any cause (e.g., age-related macular degeneration, ocular histoplasmosis, or pathologic myopia).
- Cataract in the study eye that causes visual impairment, or patients judged by the investigator as likely to undergo cataract surgery during the study period.
- The study eye is aphakic (post-vitrectomy), silicone oil-filled, or gas-filled.
- Best-corrected visual acuity (BCVA) of the non-study eye <19 ETDRS letters (approximately equivalent to Snellen 20/400) at screening and baseline.
- Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: 3+T&E Regimen
|
Experimental:Intravitreal aflibercept 2 mg/0.05 mL (Zhuochuming®), 3 monthly loading doses (W0, W4, W8). From W12: treat-and-extend (T&E) regimen. Interval extension (by 2-4 weeks, max 16 weeks) if no intraretinal/subretinal fluid on OCT and no worsening criteria. Interval maintenance if fluid persists but decreases. Interval shortening (by 2-4 weeks, min 6 weeks) if new/recurrent fluid, or BCVA loss ≥5 letters with recurrent fluid, or increase in central retinal thickness ≥100 μm. Active Comparator:Intravitreal aflibercept 2 mg/0.05 mL (Zhuochuming®), 3 monthly loading doses (W0, W4, W8). From W12: pro re nata (PRN) regimen with assessments every 4 weeks. Re-injection criteria: central retinal thickness >250 μm, or increase >50 μm from previous lowest OCT, or loss of ≥5 ETDRS letters in BCVA accompanied by an increase in CRT. |
|
Comparador Ativo: 3+PRN Regimen
|
Experimental:Intravitreal aflibercept 2 mg/0.05 mL (Zhuochuming®), 3 monthly loading doses (W0, W4, W8). From W12: treat-and-extend (T&E) regimen. Interval extension (by 2-4 weeks, max 16 weeks) if no intraretinal/subretinal fluid on OCT and no worsening criteria. Interval maintenance if fluid persists but decreases. Interval shortening (by 2-4 weeks, min 6 weeks) if new/recurrent fluid, or BCVA loss ≥5 letters with recurrent fluid, or increase in central retinal thickness ≥100 μm. Active Comparator:Intravitreal aflibercept 2 mg/0.05 mL (Zhuochuming®), 3 monthly loading doses (W0, W4, W8). From W12: pro re nata (PRN) regimen with assessments every 4 weeks. Re-injection criteria: central retinal thickness >250 μm, or increase >50 μm from previous lowest OCT, or loss of ≥5 ETDRS letters in BCVA accompanied by an increase in CRT. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
To compare the change from baseline in best-corrected visual acuity (BCVA) at week 52 between the experimental group and the control group
Prazo: Week52
|
Week52
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Compare the change from baseline in OCT-measured central retinal thickness at week 52 between the experimental and control groups
Prazo: Week 52
|
Week 52
|
|
Compare the proportion of patients achieving a ≥15-letter gain in BCVA from baseline at week 52 between the experimental and control groups
Prazo: Week 52
|
Week 52
|
|
Compare the proportion of patients with a <15-letter loss in BCVA from baseline at week 52 between the experimental and control groups
Prazo: Week 52
|
Week 52
|
|
To compare the number of injections within 52 weeks between the experimental group and the control group
Prazo: Week 52
|
Week 52
|
|
To compare the incidence and severity of adverse events (AE) and serious adverse events (SAE) during the treatment period between the experimental group and the control group
Prazo: From week 0 to week 52, plus a 30-day safety follow-up after the last dose
|
From week 0 to week 52, plus a 30-day safety follow-up after the last dose
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
Outros números de identificação do estudo
- QL-RE1-25002
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .